NICE issues draft guidance on esketamine for treatment-resistant depression for consultation

In DRAFT guidance, NICE does not recommend esketamine (with SSRI or SNRI) for treatment-resistant depression that has not responded to at least 2 different antidepressants due to insufficient evidence to compare with currently available therapies.

National Institute for Health and Care Excellence